Literature DB >> 18054932

Effectiveness of cetrorelix for the prevention of premature luteinizing hormone surge during controlled ovarian stimulation using letrozole and gonadotropins: a randomized trial.

Tsung-Hsien Lee1, Yu-Hung Lin, Kok-Min Seow, Jiann-Loung Hwang, Chii-Ruey Tzeng, Yu-Shih Yang.   

Abstract

OBJECTIVE: To evaluate the effectiveness of a GnRH antagonist in preventing premature LH surge under a letrozole and gonadotropin protocol.
DESIGN: Prospective, randomized clinical trial.
SETTING: A teaching hospital and tertiary medical center. PATIENT(S): Sixty-one patients were randomly assigned into two letrozole and gonadotropin-treated groups. These were distinguished by the absence (group I) or presence (group II) of supplementation with 0.25 mg of cetrorelix. INTERVENTION(S): Controlled ovarian stimulation with letrozole and gonadotropins, cetrorelix and intrauterine insemination. MAIN OUTCOME MEASURE(S): Rate of premature LH surge. RESULT(S): Compared with group I, the rate of premature LH surge was statistically significantly lower for group II (43.4% [13/30] vs. 19.4% [6/31]), but the amount of gonadotropins used was statistically significantly higher (817.5 +/- 28.5 vs. 907.5 +/- 27.3 IU). Patients with premature LH surge had a statistically significantly lower pregnancy rate (21.4% [9/42] vs. 0 [0/18]) relative to their unaffected counterparts. CONCLUSION(S): A flexible protocol of 0.25 mg of cetrorelix for IUI cycles appears to suppress the rate of premature LH surge during ovarian stimulation with letrozole and gonadotropins. However, the incidence of premature LH surge remains too high, and modification will be necessary before the application of cetrorelix to IVF treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18054932     DOI: 10.1016/j.fertnstert.2007.06.029

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  14 in total

1.  Does premature luteinization or early surge of LH impair cycle outcome? Report of two successful outcomes.

Authors:  Murat Sönmezer; Aylin Pelin Cil; Cem Atabekoğlu; Sinan Ozkavukçu; Batuhan Ozmen
Journal:  J Assist Reprod Genet       Date:  2009-02-18       Impact factor: 3.412

Review 2.  Cost and safety of assisted reproductive technologies for human immunodeficiency virus-1 discordant couples.

Authors:  Ming-Yih Wu; Hong-Nerng Ho
Journal:  World J Virol       Date:  2015-05-12

3.  [Effects of cetrorelix versus ganirelix in gonadotropin-releasing hormone antagonist cycles for preventing premature luteinizing hormone surges and on clinical outcomes of IVF-ET cycles].

Authors:  Jun Zhang; Xingyu Zhou; Yingxue Chen; Qingyan Zhang; Ying Li; Jing Zhe; Xin Chen; Shiling Chen
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-10-30

4.  Chronic Estrus Disrupts Uterine Gland Development and Homeostasis.

Authors:  C Allison Stewart; M David Stewart; Ying Wang; Rachel D Mullen; Bonnie K Kircher; Rui Liang; Yu Liu; Richard R Behringer
Journal:  Endocrinology       Date:  2022-03-01       Impact factor: 4.736

Review 5.  Agents for ovarian stimulation for intrauterine insemination (IUI) in ovulatory women with infertility.

Authors:  Astrid Ep Cantineau; Anouk Gh Rutten; Ben J Cohlen
Journal:  Cochrane Database Syst Rev       Date:  2021-11-05

6.  Evaluation of Role of GnRH Antagonist in Intrauterine Insemination (IUI) Cycles with Mild Ovarian Hyperstimulation (MOH): A Prospective Randomised Study.

Authors:  Leena Wadhwa; Rupali Khanna; Taru Gupta; Sangeeta Gupta; Sarika Arora; Sumi Nandwani
Journal:  J Obstet Gynaecol India       Date:  2016-02-26

Review 7.  Effectiveness of GnRH antagonist in the management of subfertile couples undergoing controlled ovarian stimulation and intrauterine insemination: a meta-analysis.

Authors:  Shan Luo; Shangwei Li; Song Jin; Ya Li; Yaoyao Zhang
Journal:  PLoS One       Date:  2014-10-09       Impact factor: 3.240

8.  Impact of gonadotropin-releasing hormone antagonist addition on pregnancy rates in gonadotropin-stimulated intrauterine insemination cycles.

Authors:  Shikha Jain; Abha Majumdar
Journal:  J Hum Reprod Sci       Date:  2016 Jul-Sep

9.  Cancer treatment using peptides: current therapies and future prospects.

Authors:  Jyothi Thundimadathil
Journal:  J Amino Acids       Date:  2012-12-20

10.  The Utrogestan and hMG protocol in patients with polycystic ovarian syndrome undergoing controlled ovarian hyperstimulation during IVF/ICSI treatments.

Authors:  Xiuxian Zhu; Hongjuan Ye; Yonglun Fu
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.